Rifabutin, a lesser-known cousin of the frontline tuberculosis drug rifampicin, may hold new life as a treatment option for multidrug-resistant tuberculosis—but only for patients carrying specific genetic signatures in the bacterium. That is the central finding of a new whole-genome sequencing study from Shenzhen, China, which maps for the first time in detail how mutations […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.